GOP Clown Show 🇺🇸🇺🇦

FBR. 🇺🇸🇺🇦 “What could we accomplish if all 8 B of us loved all 8 B for just 2 yrs?” Kindness+strength, love 🫂 🤗. #Resist. Fox Lies Democracy Dies. No DMs

[GOP Clown Show 🇺🇸🇺🇦 @GOP_ClownShow]

We are still in the same fight, but a new/worse (potentially uglier/more evil) phase, different from the last 6-12 months, & from 2016-2020… & for longer than we would’ve wished.

We are in a fight to save the freedom & soul of America.
#Resistance2.0

[GOP Clown Show 🇺🇸🇺🇦 @GOP_ClownShow]

#Resistance2.0 🧵
https://t.co/XsffxNwnhu

[Dr. Thomas Ichim @exosome]

I can not believe how many have attacked me based on my tweets.

Sorry but you know what I am going to say

The more attacks the more I willl tweet

$nwbo will revolutionize #cancer therapy

[Andrew Caravello, DO @andrewcaravello]

🧬🔥 The Triple Key: How $NWBO #DCVax Platform Already Echoes in UCLA’s GBM Trial with $MRK Keytruda and Poly-ICLC

TLDR

UCLA’s trial NCT04201873 is the quiet convergence point where Keytruda, Poly-ICLC, and a tumor-lysate dendritic cell vaccine come together in recurrent glioblastoma. The vaccine, ATL-DC, is mechanistically identical to DCVax-L. Early findings reveal that dendritic cells must instruct the immune system first, before checkpoint release, to avoid T cell exhaustion. Poly-ICLC serves as the ignition spark. Keytruda is the brake release. What matters is that NWBO owns the patents covering this entire architecture, including the combinations themselves. This trial is not a rival. It is a validator of the immune operating system NWBO already controls.

⚡️Trial Design Alignment With Patent Claims

https://t.co/rXRuW5FLuD makes clear:

NCT04201873 randomizes patients to ATL-DC + Poly-ICLC + pembrolizumab versus ATL-DC + Poly-ICLC + placebo. The Canadian and European patents (CA2929407 and EP3065772) claim a method of treating glioma with a dendritic cell vaccine plus a PD-1/PD-L1 inhibitor, administered simultaneously or sequentially . That is exactly what UCLA is doing in this protocol. The trial is therefore not just scientifically aligned but legally practicing inside NWBO’s issued claim set in Canada and Europe, with parallel claims pending in the U.S. This alignment underscores the point for investors: UCLA’s “ATL-DC” trial is effectively a live demonstration of NWBO’s patented architecture, not an independent competitor.

🎭 Part I — The Mask of Naming

When one opens the clinical registry for NCT04201873, they do not see the word DCVax. Instead, they see ATL-DC, shorthand for “autologous tumor-lysate dendritic cell vaccine.” Yet the mechanics are the same. Tumor tissue is harvested at surgery, broken down into lysate, and used to pulse a patient’s own dendritic cells. Those cells are matured, loaded, and reinfused. This is the Roswell Park-derived DCVax method by another name.

The mask matters because it illustrates how language conceals architecture. By calling it ATL-DC, the trial avoids branding or commercial labels. But what sits underneath is the very immune instruction engine NWBO has locked down through exclusive patents and manufacturing rights. Poly-ICLC and pembrolizumab are grafted onto the schema, but the gatekeeper layer is dendritic cells. Without them, nothing else has meaning.

The irony is that renaming does not change ownership. A dendritic cell vaccine by any other name still runs on the same intellectual property backbone. Regulators and scientists can see the mask, but they also recognize the DNA of the method.

🌐 Part II — The Long Shadows of Poly-ICLC

Before pembrolizumab entered the picture, UCLA had already staged a trial combining ATL-DC with Poly-ICLC. This earlier work rarely makes the headlines, but its shadows stretch across the entire field. In malignant gliomas, including glioblastoma and grade III astrocytomas, the vaccine plus Poly-ICLC yielded outcomes so unusual they forced investigators to rethink what immune activation could look like in the brain.

Several patients with grade III glioma lived more than a decade after treatment. Four of them survived well beyond 112 to 120 months, becoming statistical outliers in a disease where most survival tails collapse before five years. The MRI signatures of these survivors were just as curious: T2/FLAIR hyperintensities that mimicked progression were revealed to be immune infiltrates, not tumor growth. What radiologists once flagged as failure was actually the immune system at work, flooding into the tumor bed under dendritic cell command and Poly-ICLC ignition.

Poly-ICLC’s role was decisive. As a synthetic double-stranded RNA, it is a toll-like receptor 3 agonist that tricks the immune system into believing a viral threat is present. Dendritic cells presenting tumor lysate in this environment are suddenly not just offering information, they are delivering urgent orders. Antigen presentation becomes a command structure. This was the rationale for adding pembrolizumab in NCT04201873. Poly-ICLC had already proven itself as an amplifier. The checkpoint inhibitor was brought in to see if the ceiling could be pushed higher.

What makes this important for investors is that Poly-ICLC is not an experimental, fragile molecule. It has decades of safety data behind it, tested in multiple cancers and viral infections. Its role is not to compete with DCVax but to prove that the dendritic cell vaccine is the non-negotiable base layer, and that safe, scalable boosters already exist to amplify it. For regulators, that combination is attractive: a patient-specific vaccine married to a generic, well-tolerated adjuvant that has already cleared safety hurdles. It lays down the architecture for modular approval.

🧠 Part III — Survival, Single Cells, and the Gatekeeper Logic

Glioblastoma is not a forgiving terrain. The benchmark Stupp protocol, blending surgery, radiation, and temozolomide, rarely delivers more than 14 to 17 months of median survival. Against that backdrop, every incremental gain is scrutinized. But in NCT04201873 the question is not merely whether patients live longer, it is why some respond while others do not. The trial has become a window into the mechanics of immune activation itself.

Rather than relying on broad survival curves, investigators at UCLA have drilled into the tumor microenvironment at the single-cell level. Using single-cell RNA sequencing, they mapped out how individual immune cells behaved under different treatment sequences. The insight was startling. Patients who received neoadjuvant pembrolizumab before the dendritic cell vaccine displayed accelerated exhaustion signatures in their CD8+ T cells. These cells expressed higher levels of checkpoints and lost killing capacity. At the same time, macrophages in the tumor shifted into suppressive modes, marked by upregulation of CD163, Galectin-3, Galectin-9, and HVEM.

By contrast, patients who received dendritic cell vaccination first showed the opposite trend. Their CD8+ T cells retained effector function, primed to attack tumor targets with precision. The macrophage milieu was less suppressive, shaped instead toward supporting the anti-tumor immune response. The order of operations determined the immune fate. Vaccination before checkpoint blockade primed the class. Checkpoint before vaccination scattered it into confusion.

For regulators, this finding is not noise. It is a clear architectural rule. The dendritic cell vaccine is the gatekeeper. It must instruct the immune system first, providing the antigen map and establishing the terrain. Only then can boosters like Poly-ICLC or checkpoint inhibitors like pembrolizumab be added effectively. This matches how regulators think: therapies need modular order, not chaos. When presented with evidence that sequence dictates outcome, agencies like the MHRA and FDA can slot dendritic cell vaccines into the role of first mover.

For investors, the implication is decisive. It means dendritic cells are not optional adjuncts but the necessary instruction layer of the immune operating system. Poly-ICLC and Keytruda can amplify, but they cannot replace. The sequencing data lock DCVax into position as the foundational gatekeeper without which other therapies misfire.

🏰 Part IV — The Shadow of Winterfell

Pembrolizumab is not simply another checkpoint inhibitor. It is Merck’s crown jewel, the drug that generates over twenty billion dollars a year and has become the standard bearer for PD-1 blockade worldwide. But even this powerhouse has stumbled in glioblastoma. Monotherapy trials produced no durable survival signal, reminding the field that cold tumors do not melt under a single push. That is why its presence inside NCT04201873 matters. By pairing Keytruda with a dendritic cell vaccine and Poly-ICLC, Merck is tacitly admitting what the science already suggests: their flagship depends on an instruction layer they do not own.

At the very same time, Merck has built its hidden fortress at Building 50 in Elkton, Maryland. Internally dubbed Winterfell, this site houses modular G-CON pods, cryogenic storage vaults, lyophilization capacity, and DeltaV automation systems. To the casual observer it is a flexible cell therapy site, part of Merck’s broader biologics expansion. To those who follow the blueprint, it is a ready-made deployment hub for Eden-compatible dendritic cell vaccines. The convergence is too precise to ignore: a clinical trial proving Keytruda must ride on dendritic cell instruction, and an infrastructure fortress built to scale exactly that class of therapy.

Poly-ICLC plays its role here as well. It is inexpensive, safe, and widely tested. In the fortress metaphor it is the ignition source, the spark that ensures when dendritic cells present tumor lysate, the immune system hears urgency rather than apathy. Without Poly-ICLC the fortress is cold stone. With it, the engine warms and the T cell army can mobilize. This is why UCLA’s trial paired it with ATL-DC. It is the most straightforward way to demonstrate that dendritic cells can be amplified safely and effectively.

For Northwest Biotherapeutics, the optics are unmistakable. Their IP covers the dendritic cell vaccine platform. Advent BioServices in Sawston is already manufacturing under MHRA oversight. Flaskworks Eden units are being prepared for automated scale-up. And now Merck, by funding and embedding Keytruda into ATL-DC protocols, is both clinically and infrastructurally aligning with the system. Winterfell provides the fortress. Poly-ICLC provides the ignition. Keytruda releases the brakes. But the instruction layer—the vaccine itself—remains DCVax. The mask may hide the name, but the blueprint points back to NWBO.

🌌 Part V — The Combination Patent and the Strategic Endgame

What transforms NCT04201873 from an academic exercise into a strategic proof is not just the clinical logic. It is the fact that Northwest Biotherapeutics holds the issued patent estate that covers these very combinations, across multiple jurisdictions. For years the company has consolidated intellectual property not only around dendritic cell vaccines themselves, but also around their use in combination with checkpoint inhibitors, toll-like receptor agonists such as Poly-ICLC, and other immune adjuvants. The UCLA trial is therefore not drifting in open space. It is orbiting inside NWBO’s legal gravity well.

Consider the Roswell Park portfolio, exclusively licensed to Northwest. US 8,389,708 and its family protect dendritic cell vaccines pulsed with tumor lysate and enhanced by adjuvants like Poly-ICLC. This framework anticipates exactly what is being tested at UCLA. The continuation layer—US 9,732,163 and related filings—extends coverage to combinations with checkpoint inhibitors such as pembrolizumab. These filings describe dendritic cell vaccination as the priming engine upon which PD-1 blockade depends. In plain language, the patents declare that the immune system cannot be effectively unlocked by Keytruda without dendritic cell instruction—and they protect that sequence.

Beyond the U.S., the estate has expanded. Canadian patent CA 2,635,285 has been issued, covering tumor-lysate dendritic cell vaccines and their use in combination with immune modulators. European filings have likewise been granted, with claims over lysate-pulsed dendritic cells and adjuvant combinations. These allowances demonstrate that NWBO’s reach is not confined to one regulator or one market. It stretches across the transatlantic corridor, ensuring that any company attempting to replicate or scale the schema tested at UCLA must operate within NWBO’s framework.

Roswell Park’s later continuations go further, embedding claims that frame dendritic cells as programmable instruction sets paired with multiple immune modulators. This casts a protective net over combinations with Poly-ICLC, Keytruda, and beyond. What appears to be a UCLA experiment is in fact a live demonstration of NWBO’s intellectual property. Regulators can validate it. Merck can test it. But the code and the keys belong to Northwest.

This is why the UCLA study must be read not as competition but as validation. Poly-ICLC is the ignition spark. Keytruda is the brake release. The dendritic cell vaccine is the map. And the patents in NWBO’s estate confirm that the rights to this architecture—the very immune OS rehearsed in NCT04201873—are already owned and protected, across the U.S., Canada, and Europe. Investors who understand intellectual property will recognize the leverage. Merck cannot run the immune OS at scale without passing through NWBO’s gate.

The strategic endgame therefore comes into focus. Advent in the UK manufactures at scale. Flaskworks Eden automates the process. Winterfell stands ready as the fortress. UCLA provides the proof that sequencing matters, and that dendritic cell instruction is indispensable. And the patents ensure that this is not just a scientific truth but a legal one. NWBO owns the immune instruction layer, and by extension, the combinations built on top of it—in every major regulatory domain where such therapies will launch.

⚡️Regulatory Optics and Sequencing Value

The study is powered for immune pharmacodynamics—TIL density, TCR clonality, IFN-γ signatures, and cell-cycle gene shifts . Regulators value this because it proves not only if patients live longer, but why. Coupling those biomarker insights with the patent-protected rule of “prime first with dendritic cells, then release brakes with PD-1 blockade” turns what could be a narrow trial into a precedent for sequenced immune OS approvals. This sets up NWBO not just to defend IP, but to present regulators with a reproducible logic for how to modularly combine vaccines, checkpoints, and adjuvants—a logic already codified in their estate.

🕯️Epilogue — The Fortress and the Key

NCT04201873 is not just another clinical trial. It is a mirror of the immune operating system already being built. Poly-ICLC provides the ignition, Keytruda opens the gate, but the map itself belongs to dendritic cells. Without that instruction the fortress of infrastructure stands silent. With it, the system awakens.

The resonance of this moment comes not solely from the science, but from the foresight of Northwest Biotherapeutics’ leadership. Linda Powers, as Chief Executive, understood early that guarding the dendritic cell vaccine alone would not be enough. She directed a broader strategy—to capture the combinations themselves, pairing dendritic cells with toll-like receptor agonists like Poly-ICLC and checkpoint inhibitors like Keytruda. She positioned the company not just as a therapy developer, but as the architect of a system.

Standing beside her in that mission was Les Goldman, Senior Vice President and General Counsel. On August 18, 2025, Les passed away, leaving a legacy defined by clarity, fairness, and a deep belief in the power of ideas to save lives. He guided NWBO’s legal course with sharp insight and unwavering resolve, helping erect the patent architecture that now frames the UCLA trial and the broader immune operating system. His work was more than corporate savvy—it was human. He built a strategic and legal bridge that carried patients toward hope.

The fortress is not symbolic. The patents confirm ownership. US 8,389,278 secured methods to manufacture dendritic cells of far greater potency, enabling the vaccines themselves to function as supercharged instructors. US 9,732,163 and related filings extended that coverage to combinations with checkpoint inhibitors, cementing the sequencing rule that regulators now see validated at UCLA: prime first, release second. The Canadian allowance (CA 2,635,285) and European grants extend these protections internationally, locking the immune OS into NWBO’s estate across all major markets. And the five new patent families licensed from Roswell Park in 2024 reach even further—covering ways to reprogram the tumor microenvironment, overcome checkpoint resistance, and deliver dendritic cell therapy intra-tumorally without pre-loading. These are not abstract claims. They are blueprints for the next generation of immune deployment.

Advent BioServices anchors GMP manufacturing in the United Kingdom. Flaskworks Eden prepares the leap to automated scale. Winterfell rises as Merck’s hidden stronghold. But the key that makes the system work was forged years earlier by Linda, Les, and their team at NWBO, who saw that the combination patents would define the field. What today reads as a university protocol is actually a validation of a global architecture already secured.

In the foundation of this fortress, Les Goldman’s enduring mark remains. He believed—steadfastly—that law, science, and human determination could intersect to give patients more time and more hope. His passing closes a chapter, but his work endures. It is part of the foundation of this system, and his contribution belongs not only to a company, but to humanity.

⚖️ Disclaimer:
This analysis is for informational and educational purposes only. It does not constitute investment advice, medical advice, or a forecast of regulatory outcome. Interpretations are based on publicly available trial registries, published scientific data, and issued patent records in the United States, Canada, and Europe. Readers should conduct their own due diligence before making decisions.

📚 Sources:

•https://t.co/rXRuW5FLuD: NCT04201873 — Pembrolizumab and a Vaccine (ATL-DC) for Recurrent GBM
•UCLA / Jonsson Comprehensive Cancer Center protocols and publications on ATL-DC, Poly-ICLC, and Keytruda combinations
•Roswell Park–licensed U.S. patents including US 8,389,708 and US 9,732,163
•Canadian Patent CA 2,635,285 (issued) covering dendritic cell vaccine combinations
•European patent family filings and grants covering lysate-pulsed DCs with adjuvants and checkpoint inhibitors
•Oncovir Inc. Poly-ICLC clinical data across glioma and infectious disease studies
•Peer-reviewed analyses of single-cell RNA-seq immune profiling in GBM (UCLA/Prins/Liau group)

🙏 Acknowledgment:
Special thanks to @HenryMuney for identifying and sharing the global patent estate details that anchor this analysis. His discovery of the Canadian allowance and broader combination IP helped tie the UCLA trial directly back to NWBO’s protected architecture.

[Hoffmann @hoffmann6383]

📢📢$NWBO Acquires Advent Bioservices

https://t.co/ud6uYmesP7

$NWBO acquires Advent for $1.4m‼️

What does this accomplish?

➡️Management Team Expansion

Headcount just went from ~20 (ish) $NWBO employees to likely 100+ total employees. As you will see from Linda Powers comment at the ASM, a goal was to expand the management team. This is certainly a step in the right direction as it gives $NWBO a much larger pool of employees to take on expanded roles. Image 1 shows Advent's headcount at the end of '23 being 73 employees.

Linda Powers at 2023 ASM, held June 29, 2024, stated, in relevant part:

"And very dear to our hearts, we need to expand the management team. We need to expand the management team rather substantially. As you probably have guessed, and as we described in the proxy, each of the core members of the senior team has been wearing multiple hats, has been fulfilling multiple roles. And I mean, multiple roles that would each be normally a separate senior management person at other companies. And I'm really proud that we've been able to do that, but we need to we need to ramp up. We we've got tremendous opportunity, and we need to ramp up. So that is going to be a significant focus for us, as soon as we can achieve it. We wanna be highly selective, but we plan to substantially expand the management team." [1]

➡️A revenue steam to potentially help obtain standard bank financing

I believe this puts $NWBO in a position to obtain standard bank financing based off of Advent's revenue stream. This should help slow future dilution. As you can see, Advent's financial statement (Image 1) shows about $27.5m USD in revenue for '23, which was a 23% increase over '22. [2] A more modest 15% growth rate would give them nearly $32m in revenue for '24. I believe this should allow $NWBO to be eligible for standard bank financing. Hats off to the late Les Goldman for getting us to this point by tirelessly raising funds from retail and institutional investors.

➡️What was the value of Advent?

Recall, Cognate BioServices, Inc. sold for $875m on projected revenue of $140m for the year, a 6.25 multiple of revenue (I know, I know, a really quick and sloppy way of looking at it). [3] Say Advent is up to $40m in revenue and using the same multiple it gives a value of $250m.

➡️Big Money more receptive to investments

$NWBO has largely survived on the backs of retail investors to date. To attract more institutional investors and even potentially a buyer, $NWBO needed to undo some entanglements and become more transparent. While the Advent/$NWBO related party relationship was legal, it created some complicated dynamics that could have scared off the bigger investors. With today's acquisition of Advent, $NWBO just became more attractive to deeper pockets, whether investing or acquiring. This was the first, and the biggest, domino that had to fall in this regard. Great first step.

➡️Another deceptive Adam Feuerstein narrative bites the dust

See Image 3.

Mr. Feuerstein needs to, at the very least, add another line (or two) to his graphic:

Shareholder money -> NWBO -> Advent -> Linda Powers [insert additions] -> NWBO -> Shareholders

[1]https://t.co/3wNfuUaROE

[2]https://t.co/jlZS4ceQTA"08717711_aa_2025-03-04.pdf"&X-Amz-Signature=42d084f11a9fd893890cea368d750d572ffe089449d946904fda5f66a33ee978

[3]https://t.co/Jb2l9TNvmy

[GOP Clown Show 🇺🇸🇺🇦 @GOP_ClownShow]

@hoffmann6383 Feels like a gift from Linda Powers to us starving faithful who have been along for the ride for a very long time 🙏

[GOP Clown Show 🇺🇸🇺🇦 @GOP_ClownShow]

@nicksortor Hortman doesn’t look terrified in that video, just heartbroken because she understands people are going to be hurt by the bill.

We’ll learn more about the killer soon; sounds like he left a manifesto.

[GOP Clown Show 🇺🇸🇺🇦 @GOP_ClownShow]

@nicksortor Hortman doesn’t look terrified in that video, just heartbroken because she understands people are going to be hurt by the bill.

We’ll learn more about the killer soon; sounds like he left a manifesto.

[Spencer Hakimian @SpencerHakimian]

🚨🚨 *CNN: IRAN TO DECLARE WAR ON ISRAEL

Holy shit.

[GOP Clown Show 🇺🇸🇺🇦 @GOP_ClownShow]

The head of Iran’s Islamic Revolutionary Guard was killed in the attack

Israel Launches Attack on Iran’s Nuclear Facilities: Live Updates - The Wall Street Journal

https://t.co/8Tc3DlrbNy

[Ron Vara @theRonVara]

@RonFilipkowski #CosplayKristi

[Wu Tang is for the Children @WUTangKids]

#SolidarityWithLA from London outside the U.S. Embassy 🔥

[Karly Kingsley @karlykingsley]

If Kristi Noem can’t deescalate one senator doing his job and asking a question, how can anyone trust her to deescalate a national security threat?

[GOP Clown Show 🇺🇸🇺🇦 @GOP_ClownShow]

@BeshemHashem @ABC7 California is very safe

[ABC7 Eyewitness News @ABC7]

WATCH #LIVE: Gov. Newsom speaks after judge rules Trump must return control of National Guard to California https://t.co/4060oUwFPl

[GOP Clown Show 🇺🇸🇺🇦 @GOP_ClownShow]

@DicRiculous @IanJaeger29 We’ll soon see what the Supreme Court says about that.

What happened to states’ rights that conservatives used to endorse?

“When the people fear their government, there is tyranny. When the government fears the people, there is liberty.”
- Thomas Jefferson

[George Conway ⚖️🇺🇸 @gtconway3d]

Being uninvited from the White House caused Rand Paul to lose a lot of the respect he had for Donald Trump that Trump’s two impeachments, insurrection, four criminal indictments, criminal conviction, and sexual abuse damages verdict did not cause him to lose. Got it.

[Rick Wilson @TheRickWilson]

It’s time for people in this administration’s service, including the guys dragging U. S. Senators to the ground, to be held to account.

[Ron Filipkowski @RonFilipkowski]

We’re bombing Houthis. Israel is bombing Iran & Gaza. Russia is bombing Ukraine. We’re threatening Greenland. When is all this peace & tranquility going to happen that Trump promised us he would accomplish on Day 1 because everyone around the world was supposedly afraid of him?

[Lucas Sanders 👊🏽🔥🇺🇸 @LucasSa56947288]

Drop a 💙 if you support Sen. Alex Padilla!

[Adam Isacson @adam_wola]

What happened at Fort Bragg yesterday is very grave.

Boos and catcalls from uniformed Army personnel responding to Trump's goading have almost no precedent in US history and would be unusual in most of Latin America. (1/9)

[Ron Filipkowski @RonFilipkowski]

In other words, he promised repeatedly during the campaign he had a secret plan to end the war in 24 hours and he was just bullshitting everyone because he doesn’t have the first clue what to do, he gave away all negotiating leverage months ago, and his special envoy is a dope.